Medical Management of Uterine Fibroids

First-Line Medical Management Options

The American College of Radiology recommends estrogen-progestin oral contraceptive pills and progestin-containing intrauterine devices (IUDs) as first-line medical management options for reducing bleeding symptoms associated with uterine fibroids in patients with heavy menstrual bleeding 1, 2
Nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended for symptom management, particularly for pain control, with a strength of evidence supporting their efficacy 1, 3
Tranexamic acid is an important nonhormonal alternative that effectively reduces bleeding symptoms in patients with fibroids who cannot or prefer not to use hormonal options, with a significant reduction in menstrual blood loss 1, 2

Oral GnRH antagonists (elagolix, linzagolix, and relugolix) have emerged as effective second-line treatments that significantly reduce both bleeding symptoms and fibroid volume, with combination hormone add-back therapy to mitigate side effects 1, 2, 4
These GnRH antagonists offer advantages over parenteral GnRH agonists in terms of administration route and rapid onset of action, with a high level of evidence supporting their use 2, 5
Combination treatment with low doses of estrogen and progestin has been FDA-approved to mitigate hypoestrogenic side effects while maintaining efficacy for fibroid-related heavy menstrual bleeding 1, 5

Progesterone receptor modulators such as ulipristal acetate are effective for reducing both bleeding and bulk symptoms, with a moderate level of evidence supporting their use 1, 4
These agents can be administered intermittently, allowing for menstruation during medication breaks, with demonstrated efficacy for continuous use after 3 months and intermittent use for up to 2 years 2, 4

Fertility is suppressed during treatment with GnRH agonists and antagonists, and symptoms typically recur rapidly after cessation of therapy 1, 2
When selecting medical management options, consider the patient's desire for future fertility, severity of symptoms, size, number, and location of fibroids, and need for preoperative optimization 3, 5
The American College of Radiology recommends considering the patient's individual characteristics and medical history when selecting a treatment option 1, 5

For patients with heavy menstrual bleeding as primary symptom, start with first-line options: NSAIDs, tranexamic acid, combined hormonal contraceptives, or levonorgestrel IUD, and progress to GnRH antagonists with hormone add-back therapy if inadequate response 1, 5
For patients requiring fibroid volume reduction, GnRH agonists or antagonists are most effective, with combination hormone add-back therapy to minimize side effects 1, 4, 5
For patients preparing for surgery, short courses of GnRH agonists or antagonists effectively reduce fibroid size and correct anemia, with iron supplementation provided concurrently 1, 5

Most medical treatments provide only temporary symptom relief, with recurrence after discontinuation, and a high level of evidence supporting the need for ongoing management 1
Long-term use of GnRH agonists or antagonists without add-back therapy can lead to significant bone mineral density loss, with a strong recommendation for add-back therapy 1, 4

The American College of Radiology recommends administering an oral GnRH antagonist (relugolix 40 mg, elagolix, or linzagolix) once daily for a 12‑week (3‑month) course immediately prior to laparoscopic myomectomy, combined with continuous low‑dose estradiol/norethindrone acetate add‑back therapy to reduce fibroid volume and correct anemia. 6
Alternative oral GnRH antagonists (elagolix, linzagolix) achieve fibroid volume reductions of approximately 18 %–30 % and effectively control bleeding symptoms over the same 12‑week period. 6
A 12‑week preoperative course is considered the optimal duration, providing maximal fibroid shrinkage while maintaining acceptable bone mineral density when add‑back therapy is used. 6

Concurrent low‑dose estradiol/norethindrone acetate (E2/NETA) add‑back therapy must be started at the same time as the GnRH antagonist to prevent severe hypo‑estrogenic symptoms (e.g., hot flashes, headaches, hypertension) and clinically significant loss of bone mineral density. [6][7]
GnRH antagonist monotherapy without add‑back should not be continued beyond a few months because of unacceptable bone loss and intolerable vasomotor symptoms. [6][7]

Tranexamic acid (approximately 1300 mg orally three times daily during bleeding episodes) should be added if breakthrough bleeding persists despite adequate GnRH antagonist therapy. 6

Menstrual bleeding typically ceases within about 7 days after initiating therapy, providing rapid symptom control.
After the 12‑week course, fibroid volume is expected to decrease by 18 %–30 %, which translates into reduced intra‑operative blood loss, shorter operative time, and a lower risk of postoperative anemia. 6
Hemoglobin (or equivalent anemia marker) should be measured at baseline and again at 4–6 weeks to verify correction of anemia before surgery.

Patients should be informed that fertility is suppressed during GnRH antagonist treatment; contraception is therefore unnecessary, and normal reproductive function resumes after discontinuation. 6
Fibroid regrowth and symptom recurrence occur rapidly after stopping therapy; consequently, definitive surgery should be scheduled promptly after the 12‑week regimen. 6

Both oral GnRH antagonist protocols and GnRH agonist (e.g., leuprolide) regimens require add‑back therapy when treatment extends beyond a few months to protect bone health. 6